REG - RTW Biotech Opp. - Additional investment in Windward Bio

RTW Biotech OpportunitiesAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260508:nRSH4947Da&default-theme=true

RNS Number : 4947D  RTW Biotech Opportunities Ltd  08 May 2026

LEI: 549300Q7EXQQH6KF7Z84

8 May 2026

RTW Biotech Opportunities Ltd

Additional investment in Windward Bio

·      $165 million crossover financing to advance clinical studies in
asthma and COPD

·      RTW Bio investing $1.7 million as part of the financing round

·      As at 31 March 2026, Windward Bio represented 0.6% of the
Company's NAV

 

RTW Biotech Opportunities Ltd ("the Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to the note an additional investment in the $165 million crossover financing
of private portfolio company Windward Bio ("Windward"). Windward is a private,
clinical-stage biotechnology company committed to improving outcomes for
people living with serious immunological diseases. RTW Bio first invested in
Windward's Series A launch in January 2025 and is investing $1.7 million as
part of this financing.

Lead program WIN378 is an antibody designed to treat asthma and chronic
obstructive pulmonary disease (COPD). The drug has been engineered for an
extended half-life, enabling twice-yearly subcutaneous dosing, a meaningful
step forward from the monthly administration required by most current
biologics. It is currently being evaluated in a Phase 2/3 asthma study, with
initial readouts expected in the second half of 2026. If approved, WIN378
would be the first ultra long-acting anti-TSLP antibody available to patients.

 

As at 31 March 2026, Windward represented 0.6% of the Company's NAV.

 

Rod Wong, CIO of RTW Investments, said, "We are pleased to further support
Windward Bio as it advances a differentiated portfolio of long‑acting
immunology therapies with the potential to meaningfully improve outcomes for
patients. WIN378 has the profile we look for in a best-in-class asset: a
well-validated target, a clear durability advantage over existing treatments,
and compelling clinical trial data. This financing round will position the
Windward team well to set a new standard of care for patients with asthma and
COPD."

 

The announcement can be found here
(https://www.globenewswire.com/news-release/2026/05/04/3286605/0/en/windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential.html)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Nathan Brown

 Duncan Monteith

 George Shiel

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUSSEFMWEMSEFI



            Copyright 2019 Regulatory News Service, all rights reserved